# Valley Ventures

> Valley Ventures is a VC fund in Phoenix backing Health Care and Biotechnology. See 28 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Phoenix, United States
- Total investments: 28
- Last investment: Feb 2024
- Lead investor: 14%
- Last fund: Oct 2002
- Last updated: Aug 2026
- Website: http://www.valleyventures.com

Valley Ventures is a family of institutionally-funded venture capital partnerships that have operated under the Valley name since 1985. Committed capital in all current and past funds exceeds $95 million. The General Partner is a team of experienced venture capitalists and managers dedicated to the achievement of superior investment returns byassisting emerging growth companies in Arizona and the Southwest. Whereas all existing committed capital of Valley Ventures has been deployed or allocated to portfolio companies, the General Partner remains active in counseling and referring companies (especially in the life science area) regarding their capital formation needs. Valley Ventures maintains its home office in Phoenix, AZ.

## Contacts

5 contacts available for Valley Ventures. Shizune tracks 1 team members at Valley Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/valley-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 11% |
| Biotechnology | 3 | 11% |
| FinTech | 2 | 7% |
| Medical | 2 | 7% |
| Software | 2 | 7% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 29% |
| Series B | 5 | 18% |
| Series C | 3 | 11% |
| Seed | 2 | 7% |
| Series D | 2 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 43% |
| Israel | 1 | 4% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Terry Winters | partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NayaOne | NayaOne is a fintech platform developer focused on delivering financial goods and services through collaborative efforts. The company's software enables financial institutions to quickly design and securely analyze new proposals before scaling them to production, giving businesses the freedom to respond and adapt to changing financial markets. | $4.7M | Series A | Feb 28, 2024 |  |
| NayaOne | NayaOne is a fintech platform developer focused on delivering financial goods and services through collaborative efforts. The company's software enables financial institutions to quickly design and securely analyze new proposals before scaling them to production, giving businesses the freedom to respond and adapt to changing financial markets. | $4.7M | Seed | Feb 28, 2024 |  |
| Refine Intelligence | Refine Intelligence has developed a novel approach to help banks reduce the growing operational costs of financial crime. Their proprietary AI scans anti-money laundering alerts from transaction monitoring systems and “greenflags” customers’ legitimate activity to dramatically reduce investigation time, and can also be used to protect against checkfraud, scams and money mules. | $13M | Seed | Nov 14, 2023 |  |
| Fitnet | Fitnet delivers a personal fitness experience to mobile combining biometric sensors, fitness coaching, and online workout buddies. Its unique technological approach converts a mobile webcam into a biometric sensor capable of scoring an individual while they work out with a human trainer. The Fitnet application is used in over 190 countries and itsclients have collectively burned over 10 million calories since the launch on January 1, 2014. | $1.4M | Series A | Apr 15, 2014 |  |
| Heyo | Heyo, Inc. was formerly known as Lujure Media, Inc. Heyo helps you easily create Facebook contests, sweepstakes & mobile-optimized landing pages to help you get more fans, leads, and sales. Facebook is the premier network for small businesses and large businesses to grow their communities, and Facebook fan pages help facilitate this growth.Heyo helps companies customize their fan pages using their highly intuitive software. Their Fan Page Builder on Steroids allows users to drag and drop custom Facebook fan pages together in minutes. Mobile is the future. And Heyo is an industry leader in Mobile App development, creating a Breakthrough Mobile App Creator, as well as creating the ability for Facebook fan pages to render on Mobile devices. Heyo makes it super simple to put any kind of message directly into your customers' pockets. Use Heyo to easily create Sweepstakes, Contests, and Campaign apps that publish to Mobile, Facebook, and anywhere on the web. Heyo's Simply Remarkable Website Builder is everything you've ever needed to build your website since you first clicked a mouse (and more!). |  | Series A | Mar 18, 2014 |  |
| HTG Molecular Diagnostics | HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profilehundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona. | $16.2M | Series D | Jul 13, 2011 |  |
| HTG Molecular Diagnostics | HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profilehundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona. | $2.8M | Series C | Nov 28, 2008 |  |
| Regenesis Biomedical | Regenesis Biomedical a medical technology company that focuses on developing and marketing noninvasive regenerative medicine products. The company offers Provant Therapy System, a medical device that aids in reduction of pain and swelling of skin and soft tissues following surgery. Its customers include health care facilities and providers thatserve patients being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home healthcare agencies, and wound care clinics.Regenesis Biomedical was founded in 1996 and is headquartered in Scottsdale, Arizona. | $2.8M | Series B | May 22, 2008 |  |
| AmpliMed Corporation | AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog smallmolecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona. | $5M | Series C | Jan 14, 2008 |  |
| HTG Molecular Diagnostics | HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profilehundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona. | $5.6M | Series C | Oct 08, 2007 |  |

10 of 28 investments shown.

## Co-investors
- [Solstice Capital](https://shizune.co/investors/profile/solstice-capital) — VC Fund, 8 deals together
- [Carthona Capital](https://shizune.co/investors/profile/carthona-capital) — VC Fund, 3 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 3 deals together
- [EJF Capital](https://shizune.co/investors/profile/ejf-capital) — VC Fund, 3 deals together
- [Mission Ventures](https://shizune.co/investors/profile/mission-ventures) — VC Fund, 3 deals together
- Biotech Insight Ventures — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Valley Ventures invest in?

Valley Ventures invests primarily in Health Care, Biotechnology and FinTech startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Valley Ventures?

Public channels for Valley Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Valley Ventures?

The team at Valley Ventures includes Terry Winters (partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co